AZNAstraZenecaSigning up patients
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Newly Diagnosed Multiple Myeloma (NDMM)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 750 (planned)
- Started
- Sep 24, 2026
- Main results expected
- Nov 2, 2028
- Fully finished
- Nov 17, 2039
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS)
Measured over: Up to approximately 13 years.
Minimal Residual Disease (MRD) negative Complete Response Rate (CRR)
Measured over: Up to approximately 13 years.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07735637 · record last updated 2026-10-21 · checked 2026-11-09 15:47 UTC